Breathe Well Live Well
|
FDA advisers recommend approval of asthma drug for adults
Pharmacy Today, American Pharmacists Association, pharmacist.com An FDA advisory committee has recommended the agency approve Teva Pharmaceutical's experimental drug reslizumab for severe asthma in patients aged 18 years and older. Reslizumab is an antibody drug designed to be given intravenously once every … |
View full post on asthma – Google News
Medscape |
FDA Panel Backs Reslizumab for Adults With Severe Asthma
Medscape If approved by the FDA, it would be the third monoclonal antibody approved for asthma, after mepolizumab and omalizumab. Reslizumab binds to human interleukin-5 (IL-5). Several cytokines can affect eosinophils, but IL-5 is the main cytokine involved in … FDA experts endorse Teva's asthma drug, but reject use in key patient group FDA advisory panel recommends Teva asthma antibody FDA advisers recommend approval of Teva asthma drug in adults |
View full post on asthma – Google News
Fox News |
FDA advisers recommend approval of Teva asthma drug in adults
Fox News An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's. The panel voted unanimously that the drug should not be approved for children aged 12 to 17. US FDA advisers recommend approval of Teva asthma drug for adults FDA Advisory Committee Recommends Approval of Teva's Asthma Biologic Reslizumab |
View full post on asthma – Google News
Reuters |
US FDA advisers recommend approval of Teva asthma drug for adults
Reuters An advisory committee to the U.S. Food and Drug Administration recommended on Wednesday that the agency approve Teva Pharmaceutical Industries Ltd's <TEVA.TA) experimental drug reslizumab for severe asthma in patients aged 18 and older. Ad Comm tomorrow for Teva's asthma candidate reslizumab |
View full post on asthma – Google News
JAMA: The Journal of the American Medical Association |
Study compares combination treatments for African-American adults with asthma
Pharmacy Today, American Pharmacists Association, pharmacist.com The primary outcome was time to asthma exacerbation that required oral or parenteral corticosteroids. The results showed no difference between LABA plus ICS compared with tiotropium plus ICS in the primary outcome. There were also no significant … LABAs, tiotropium perform similarly in black patients with asthma Anticholinergic vs Long-Acting ?-Agonist in Combination With Inhaled … Study Compares Combination Treatments for Black Adults with Asthma |
View full post on asthma – Google News
Medical Xpress |
Study compares combination treatments for black adults with asthma The JAMA …
EurekAlert (press release) Among black adults with asthma treated with an inhaled corticosteroid, adding a long-acting beta-agonist did not improve the time to an asthma exacerbation compared with adding the anticholinergic tiotropium, according to a study in the October 27 … Asthma: LABA + Steroids Not a Winning Combo for Blacks |
View full post on asthma – Google News
Medical Xpress |
Study compares combination treatments for black adults with asthma
Medical Xpress Among black adults with asthma treated with an inhaled corticosteroid, adding a long-acting beta-agonist did not improve the time to an asthma exacerbation compared with adding the anticholinergic tiotropium, according to a study in the October 27 … |
View full post on asthma – Google News
Washington University in St. Louis News |
In kids, young adults with asthma, pay attention to weight gain
Washington University in St. Louis News Robert Strunk, MD, examines LeBron Reed, a patient with asthma. Strunk, of Washington University School of Medicine in St. Louis, led a study showing the importance of children with asthma maintaining healthy weight as they grow into young adults. |
View full post on asthma – Google News
|
Tift Regional offers new procedure to treat adults with severe asthma
Tifton Gazette TIFTON – Tift Regional Medical Center (TRMC) now offers a new outpatient procedure called Bronchial Thermoplasty (BT) which reduces asthma attacks in adult patients with severe asthma and is shown to improve asthma-related quality of life for people … |
View full post on asthma – Google News
| Related Articles |
Leukotriene-Receptor Antagonists Versus Placebo in the Treatment of Asthma in Adults and Adolescents: A Systematic Review and Meta-Analysis.
Ann Intern Med. 2015 Sep 22;
Authors: Miligkos M, Bannuru RR, Alkofide H, Kher SR, Schmid CH, Balk EM
Abstract
Background: Leukotriene-receptor antagonists (LTRAs) are recommended as an alternative treatment in patients with mild asthma, but their effect compared with placebo is unclear.
Purpose: To determine the benefits and harms of LTRAs as monotherapy or in combination with inhaled corticosteroids compared with placebo in adults and adolescents with asthma.
Data Sources: MEDLINE and the Cochrane Central Register of Controlled Trials from inception through June 2015.
Study Selection: Peer-reviewed, English-language, randomized, controlled trials in patients with asthma that reported the effect of LTRAs versus placebo on measures of asthma control.
Data Extraction: Three researchers extracted data on study population, interventions, outcome measures, and adverse events. One researcher assessed risk of bias.
Data Synthesis: Of the 2008 abstracts that were screened, 50 trials met eligibility criteria. Random-effects meta-analyses of 6 trials of LTRA monotherapy showed that LTRAs reduced the risk for an exacerbation (summary risk ratio [RR], 0.60 [95% CI, 0.44 to 0.81]). In 4 trials of LTRAs as add-on therapy to inhaled corticosteroids, the summary RR for exacerbation was 0.80 (CI, 0.60 to 1.07). Leukotriene-receptor antagonists either as monotherapy or add-on therapy to inhaled corticosteroids increased FEV1, whereas FEV1 percentage of predicted values was only improved in trials of LTRA monotherapy. Adverse event rates were similar in the intervention and comparator groups.
Limitation: Variation in definitions and reporting of outcomes, high risk of bias in some studies, heterogeneity of findings, possible selective outcome reporting bias, and inability to assess the effect of asthma severity on summary estimates.
Conclusion: Leukotriene-receptor antagonists as monotherapy improved asthma control compared with placebo, but which patients are most likely to respond to treatment with LTRAs remains unclear.
Primary Funding Source: National Institutes of Health.
PMID: 26390230 [PubMed – as supplied by publisher]
View full post on pubmed: asthma